Galcanezumab (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Galcanezumab" in English language version.

refsWebsite

Global rank English rank

3web.archive.org

1^st place

3fda.gov

447^th place

338^th place

2organon.com

low place

1hres.ca

low place

1nih.gov

4^th place

1europa.eu

68^th place

117^th place

1ama-assn.org

3,257^th place

3,398^th place

1handle.net

102^nd place

76^th place

1medlineplus.gov

1,581^st place

1,299^th place

1cnbc.com

220^th place

155^th place

1reuters.com

49^th place

47^th place

1pharmaceutical-technology.com

low place

ama-assn.org

"Statement on a Nonproprietary Name Adopted by the USAN Council - Galcanezumab", American Medical Association.

cnbc.com

"US FDA approves Lilly migraine drug at a price that is the same as its rivals". CNBC. Reuters. 28 September 2018. Retrieved 29 September 2018.

europa.eu

ema.europa.eu

"Emgality EPAR". European Medicines Agency (EMA). 24 September 2018. Retrieved 28 April 2020. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.

fda.gov

"FDA approves first treatment for episodic cluster headache that reduces the frequency of attacks" (Press release). U.S. Food and Drug Administration (FDA). 4 June 2019. Archived from the original on 7 December 2019. Retrieved 6 June 2019. This article incorporates text from this source, which is in the public domain.
"Drug Trials Snapshots: Emgality". U.S. Food and Drug Administration (FDA). 23 October 2018. Archived from the original on 7 December 2019. Retrieved 7 December 2019. This article incorporates text from this source, which is in the public domain.

accessdata.fda.gov

"Drug Approval Package: Emgality (galcanezumab-gnlm)". U.S. Food and Drug Administration (FDA). 27 September 2018. Archived from the original on 7 December 2019. Retrieved 7 December 2019.

handle.net

hdl.handle.net

World Health Organization (2016). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 76". WHO Drug Information. 30 (3). hdl:10665/331020.

hres.ca

hpr-rps.hres.ca

"Summary Basis of Decision (SBD) for Emgality". Health Canada. 23 October 2014. Retrieved 29 May 2022.

medlineplus.gov

"Galcanezumab-gnlm Injection: MedlinePlus Drug Information". medlineplus.gov. Retrieved 26 July 2024.

nih.gov

dailymed.nlm.nih.gov

"Emgality- galcanezumab-gnlm injection, solution". DailyMed. 11 March 2021. Retrieved 29 April 2024.

organon.com

"Organon & Lilly Enter Commercialization Agreement in Europe for Two Migraine Medicines". Organon. Retrieved 22 August 2024.
"Organon & Lilly Expand Migraine Commercialization Agreement to 11 Additional Markets". Organon. Retrieved 22 August 2024.

pharmaceutical-technology.com

"AffaMed signs deal for Lilly's Galcanezumab in Mainland China". Pharmaceutical Technology. 18 January 2023. Retrieved 26 July 2024.

reuters.com

Erman M (4 June 2019). "FDA approves Lilly's migraine drug as first ever cluster headache treatment". Reuters. Retrieved 28 April 2020.

web.archive.org

"FDA approves first treatment for episodic cluster headache that reduces the frequency of attacks" (Press release). U.S. Food and Drug Administration (FDA). 4 June 2019. Archived from the original on 7 December 2019. Retrieved 6 June 2019. This article incorporates text from this source, which is in the public domain.
"Drug Approval Package: Emgality (galcanezumab-gnlm)". U.S. Food and Drug Administration (FDA). 27 September 2018. Archived from the original on 7 December 2019. Retrieved 7 December 2019.
"Drug Trials Snapshots: Emgality". U.S. Food and Drug Administration (FDA). 23 October 2018. Archived from the original on 7 December 2019. Retrieved 7 December 2019. This article incorporates text from this source, which is in the public domain.